Kurs
+2,36%
Kurs
+2,36%
Open
34,24
High
35,57
Low
32,65
Close
34,51
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
| Tid* | ||
| 2026-03-05 | 06:00 | Bokslutskommuniké 2025 |
| 2025-11-26 | 06:00 | Kvartalsrapport 2025-Q3 |
| 2025-09-17 | 06:00 | Kvartalsrapport 2025-Q2 |
| 2025-06-25 | N/A | Årsstämma |
| 2025-06-10 | 06:00 | Kvartalsrapport 2025-Q1 |
| 2025-03-05 | 06:00 | Bokslutskommuniké 2024 |
| 2024-12-20 | - | Extra Bolagsstämma 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-09-12 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | Kvartalsrapport 2024-Q1 |
| 2024-06-27 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2024-06-26 | - | Årsstämma |
| 2024-03-20 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-09-26 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-21 | - | Årsstämma |
| 2023-06-21 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-30 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-12-09 | - | Extra Bolagsstämma 2022 |
| 2022-10-26 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-19 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2022-04-17 | - | Årsstämma |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-12-29 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-09-08 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-14 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2021-04-13 | - | Årsstämma |
| 2021-02-09 | - | Bokslutskommuniké 2020 |
| 2020-12-14 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-01 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2020-06-30 | - | Årsstämma |
| 2020-06-30 | - | Kvartalsrapport 2020-Q1 |
| 2019-12-20 | - | Extra Bolagsstämma 2019 |
| 2019-06-27 | - | Årsstämma |
| 2019-06-03 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2018-07-02 | - | Split SOFTX 1:50 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2021-03-23 15:49:44
SoftOx Solutions AS ("SoftOx") is pleased to announce that the enrolment of
study participants for the clinical investigation «SWIS-02» has been completed.
The study, which has been conducted at Bispebjerg University Hospital is a
confirmatory clinical investigation to document safety and performance of SoftOx
Wound Irrigation Solution ("SWIS") compared to Normal Saline (NS) in a human
wound model. It is a confirmative study and last of two clinical studies on
"SWIS".
We are very pleased to have completed this enrolment because of the ongoing
lockdown in Denmark, which were affecting our recruitment pace. "With this
pivotal trial we are eagerly looking forward to examining and analyse the study
data and report on the results later in Q2-2021", says Glenn Gundersen, Medical
Director of SoftOx.
SWIS is under development to become a medical device intended for wound rinsing
and moistening to prevent infections in all types of acute wounds, such as
abrasions, cuts, burns and surgical wounds.
For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599
About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth
Oslo. Our Vison is "Helping the world fighting infections - developing new ways
of eradicating infections and fighting antimicrobial resistance". We are working
to combat major threats to human health, namely the emergence of antimicrobial
resistance (AMR), biofilm infections in chronic wounds and the spread of
viruses. For more information on SoftOx, visit www.soft-ox.com